January 30, 2001
AmeriPath Presents at the 2001 U.S. Bancorp Piper Jaffray Healthcare Conference
James C. New, Chairman & CEO, January 30, 2001 at 2:00 p.m. EDT
FOR IMMEDIATE RELEASE
Michelle D. Getty
Investor Relations
AmeriPath, Inc.
561-845-1850
E-mail: invrel@ameripath.com
Riviera Beach, FL, January 29, 2001 - AmeriPath Inc,
(NASDAQ: PATH), the nation's largest company focused
on providing anatomic pathology, cancer diagnostic and
related healthcare information services, announced today
that Chairman and CEO, James C. New, will participate
in the 2001 U.S. Bancorp Piper Jaffray Health Care Conference
at the Pierre Hotel in New York City on January 30, 2001. Mr.
New is scheduled to deliver the Company's presentation
at 2:00 p.m. EDT. A live webcast of the presentation
will be accessible on-demand through the website www.investorconference.com
in the form of a slide show with an audio component. The
webcast will also be accessible on the AmeriPath website,
www.ameripath.com.
AmeriPath, Inc. is the nation's largest company focused
on providing anatomic pathology, cancer diagnostic and
related healthcare information services to physicians,
hospitals, national clinical laboratories and managed
care organizations. The Company's 426 physicians
provide medical services through 42 outpatient pathology
laboratories, 224 hospital inpatient laboratories, and
64 outpatient surgery centers in 21 states.
.......................................................................................................
The statements contained in this press
release are "forward-looking
statements" which are based on current beliefs and expectations.
Past performance is not necessarily indicative of future
results. In addition, forward-looking statements - which
are identified by words such as "may", "should", "believe," "expect," "anticipate" and
similar expressions -- are subject to a number of risks
and uncertainties which could cause actual results to
differ materially from historical results or those expected
or anticipated. These include risks and uncertainties
relating to satisfaction of closing conditions, demand
for pathology services, pricing, federal and state regulation
(and compliance), reimbursement rates, government and
third party payments, the ability to attract, motivate,
and retain pathologists, dependence upon pathologists
and contracts, the development and expansion of managed
care and national clinical lab contracts, completion
and integration of acquisitions and affiliations (and
achievement of planned or expected synergies), competitive
factors and technology. Further information regarding
risks, uncertainties and other factors that could affect
the Company's financial results, or could cause actual
results to differ materially from those expected or anticipated,
are included in the Company's Form 10-K for the year
ended December 31, 1999 and subsequent filings with the
SEC.
